Not a practical option

Earlier this week, or maybe it was last week, I saw several articles on this new intraoperative radiation for breast cancer. This is when a radioactive probe is inserted into the breast during surgery and allows the patient to skip traditional radiation. Of course, they may still need chemotherapy and other treatments.The first articles I saw touted its benefits. I was a bit pessimistic about this. I have heard about it and think it is approved in the US (but I am no doctor so don't think I know all about this). It is only for certain early stage breast cancers so it is not for everyone.The reason for this hype is that it was just approved in the UK's NHS. And then I just saw this article about a UK doctor's thoughts on this:"The treatment, given approval for NHS use in draft guidance by the National Institute for Health and Clinical Excellence, would benefit up to 36,000 people nationwide.The technique, called intra-operative radiation, is suitable only for patients who have caught their cancer early...""...The initial price of the treatment is expensive, with each probe costing £500,000.The procedure is performed during surgery.Once the tumour is removed, a probe is inserted into the breast and delivers radiation to the site of the cancer for about half an hour."That is when I fell off my chair. Am I understanding this correctly? Each probe costs  £500,000. Clearly it must mean the entire big instrument. Not just an individual probe. But...
Source: Caroline's Breast Cancer Blog - Category: Cancer Tags: breast cancer treatment expensive radiation Source Type: blogs

Related Links:

In conclusion, the addition of PPIs to the treatment regimen of breast cancer appears to be a promising strategy to potentiate the efficacy of chemotherapy and may suppress cancer metastasis. PMID: 31955147 [PubMed - in process]
Source: Acta Pharmaceutica - Category: Drugs & Pharmacology Authors: Tags: Acta Pharm Source Type: research
ConclusionsA majority of IBC patients in our study presented with node-positive disease, and for those presenting with cN2-3 disease, more extensive axillary surgery is potentially associated with improved survival. For cN0 patients, however, more extensive axillary surgery was not associated with a survival benefit, suggesting an opportunity for more personalized care.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S Abstract With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA)...
Source: Journal of Carcinogenesis - Category: Cancer & Oncology Tags: J Carcinog Source Type: research
Publication date: Available online 18 January 2020Source: Redox BiologyAuthor(s): Mohamad Assi, Suzanne Dufresne, Amélie RébillardAbstractIn this paper of the special issue dedicated for the Olympics 2020, we put the light on an exciting facet of exercise-oncology, which may still be unknown to some audience. Accumulating convincing evidences show that exercise reduces cancer progression and recurrence mainly in colon and breast cancer patients. Interestingly, the positive effects of exercise on cancer outcomes were mainly observed when patients practiced vigorous exercise of 6 METs or more. At the molecular ...
Source: Redox Biology - Category: Biology Source Type: research
We describe the adaptation of a model-based design for identifying the maximum tolerated dose combination that efficiently moves from the initial phase in an advanced disease population to the second phase in the target population. Operating characteristics demonstrate the ability of the method to accurately predict true maximum tolerated dose combinations in a high percentage of trials with reasonable sample sizes, while treating participants at and around desirable combinations. The proposed design is a practical, early-phase, adaptive method for use with drug combination dose finding in the presence of shifting patient ...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Contemp Clin Trials Commun Source Type: research
CONCLUSION: SM bioenergetics and oxidative capacity in response to PFE are not impaired following anthracycline treatment. Abnormal SM composition (increased thigh and lower leg IMF-to-SM ratio) may be an important contributor to reduced peak VO2 during whole-body exercise among anthracycline-treated BC survivors. IMPLICATIONS FOR PRACTICE: Peak oxygen consumption (peak VO2 ) is reduced in breast cancer (BC) survivors and is prognostic of increased risk of cardiovascular disease-related and all-cause mortality. Results of this study demonstrated that in the presence of deficits in peak VO2 1 year after anthracycline t...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Abstract BACKGROUND: In the absence of randomized controlled trials, real-world evidence may aid practitioners in optimizing the selection of therapy for patients with cancer. The study's aim was to determine real-word use, as well as compare effectiveness, of single-agent and combination chemotherapy as palliative treatment for female patients with metastatic breast cancer (mBC). MATERIALS AND METHODS: Using administrative claims data from the Symphony Health's Integrated Oncology Dataverse, female patients with mBC treated with at least one chemotherapy-only treatment (COT) between January 1, 2013, and Dece...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast cancer. The primary objective was to determine the maximum tolerated dose (MTD) of RO4929097. Secondary objectives were to determine real-time pharmacokinetics of RO4929097 and paclitaxel, safety and pathologic (pCR) complete response to study treatment. Eligible patients, initiated carboplatin at AUC 6 administered intravenously (IV) on day 1, weekly paclitaxel at 80  mg/m2 IV and RO4929097 10 mg dai...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Conclusions Sentinel lymph node identification using preoperative scintigraphy and intraoperative use of gamma probe seems to be a feasible and efficient method in terms of differentiating patients that require axillary lymph node dissection during breast cancer surgery, even when they have received neoadjuvant chemotherapy. Further large prospective studies allowing subgroup analyses are warranted.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
This study was designed to investigate the role and therapeutic implications of miR-151-5p in breast cancer. The results of the present study revealed that miR-151-5p is significantly downregulated in breast cancer tissues and cell lines. Overexpression of miR-151-5p in SK-BR-3 and CAMA-1 cells inhibits their proliferation and colony formation. Wound heal and transwell assays showed that miR-151-5p inhibits the migration and invasion of the SK-BR-3 and CAMA-1 breast cancer cells. TargetScan analysis followed by the dual luciferase assay confirmed SOCS5 to be the target of miR-151-5p in breast cancer. The expression of SOCS...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
More News: Blogging | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Health | National Institute for Health and Clinical Excelle